ARCH VENTURE MANAGEMENT LLC
Q1 2026 Form 13-F
CHICAGO, ILLINOIS
CIK 0001274403
· CRD 158196
· Exempt reporting adviser
$677.1M Reported Value Total
ARCH VENTURE PARTNERS reports under management (AUM).
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
ARCHVENTURE.COM
Source: Form ADV filed 2026-03-30
Reported value
$677.1M
Quarter over quarter
+10.2%
Holdings
10
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Mark Mcdonnell
Managing Director, CFO and CAO
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 15, 2026 |
| Form | 13F-HR |
| Reported value | $677.1M |
| Positions | 10 |
| Change in reported value | +3.9% |
| New positions | 1 |
| Exited positions | 0 |
| Position turnover | 10.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
17 | $1.6B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
12 | $1.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
10 | $677.1M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
9 | $651.7M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
9 | $492.4M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
11 | $299.1M |
|
Q1 2025 13F
Filed May 15, 2025
|
9 | $206.2M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
9 | $230.2M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
9 | $260.6M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
9 | $266.0M |
|
Q1 2024 13F
Filed May 15, 2024
|
8 | $80.3M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
7 | $163.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
7 | $154.0M |
|
Q2 2023 13F
Filed Aug 9, 2023
|
6 | $162.0M |
|
Q1 2023 13F
Filed May 15, 2023
|
8 | $207.2M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
8 | $390.4M |
|
Q3 2022 13F
Filed Nov 10, 2022
|
10 | $771.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
10 | $820.6M |
|
Q1 2022 13F
Filed May 13, 2022
|
8 | $699.8M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
9 | $945.3M |
8 earlier quarters on file — choose one from the quarter menu above.
Top 10 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MAZE MAZE THERAPEUTICS INC | $123.0M | 18.16% |
| 2 | RAPP RAPPORT THERAPEUTICS INC | $116.7M | 17.23% |
| 3 | VIR VIR BIOTECHNOLOGY INC | $115.7M | 17.09% |
| 4 | ERAS ERASCA INC | $114.7M | 16.95% |
| 5 | BEAM BEAM THERAPEUTICS INC | $108.2M | 15.98% |
| 6 | LYEL LYELL IMMUNOPHARMA INC | $65.1M | 9.62% |
| 7 | GENB GENERATE BIOMEDICINES INC | $24.3M | 3.59% |
| 8 | TXG 10X GENOMICS INC | $4.6M | 0.68% |
| 9 | GOSS GOSSAMER BIO INC | $2.6M | 0.39% |
| 10 | QTTB Q32 BIO INC | $2.1M | 0.3% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.